Cellectar Biosciences (CLRB) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLRB shares.
View CLRB analyst ratings or view top-rated stocks.

1 brokers have issued 1 year price objectives for Cellectar Biosciences' stock. Their CLRB share price forecasts range from $4.00 to $10.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 165.2% from the stock's current price.
View analysts price targets for CLRB or view top-rated stocks among Wall Street analysts.

Cellectar Biosciences' stock was trading at $1.71 at the start of the year. Since then, CLRB stock has increased by 54.4% and is now trading at $2.64.
View the best growth stocks for 2023 here.

Cellectar Biosciences saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 482,200 shares, an increase of 238.4% from the August 31st total of 142,500 shares. Based on an average trading volume of 620,200 shares, the short-interest ratio is presently 0.8 days. Approximately 5.2% of the shares of the stock are short sold.
View Cellectar Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CLRB earnings forecast.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) issued its quarterly earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.04.

Cellectar Biosciences shares reverse split on Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLRB stock can currently be purchased for approximately $2.64.

Cellectar Biosciences (NASDAQ:CLRB) has a market capitalization of $25.71 million. The biopharmaceutical company earns $-28,600,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The official website for the company is www.cellectar.com. The biopharmaceutical company can be reached via phone at (608) 441-8120, via email at ir@cellectar.com, or via fax at 608-441-8121.